The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Antibody therapies for AML and MDS
Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, outlines the use of monoclonal antibodies in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), in particular highlighting the use of sabatolimab and magrolimab. Sabatolimab is an antibody therapy targeting TIM-3. Magrolimab is a first-in-class investigational monoclonal antibody targeting CD47. Dr Brunner discusses the use of these therapies and comments on their efficacy in patients with high-risk mutations, as well as giving an overview of other antibody therapies and combinations which are under investigation. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Andrew M. Brunner, MD, has participated in consultancy work for Novartis, Acceleron, Agios, BMS/Celgene and Takeda.
